Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881200 | 1.00 | AR (0.77) | AR | |
| Hydrochloric Acid SCHEMBL3603359 | 0.99 | AR (0.75) | AR | |
| Hydrochloric Acid SCHEMBL3597436 | 0.99 | AR (0.75) | AR | |
| SCHEMBL3610492 | 0.96 | AR (0.71) | AR | |
| SCHEMBL3615716 | 0.87 | AR (1.00) | AR | |
| SCHEMBL3597733 | 0.87 | AR (1.00) | AR | |
| SCHEMBL3602902 | 0.87 | AR (1.00) | AR | |
| SCHEMBL3607507 | 0.85 | AR (0.81) | AR | |
| Hydrochloric Acid SCHEMBL3610050 | 0.84 | AR (0.76) | AR | |
| SCHEMBL4376040 | 0.84 | AR (0.69) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101248069-A | Androgen receptor modulators and methods of treating diseases therewith | ACADIAN PHARMACEUTICALS INC (US) | 2008-08-20 | — | — | CN | claimed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | claimed |
| CN-101248069-A | Androgen receptor modulators and methods of treating diseases therewith | ACADIAN PHARMACEUTICALS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIAN PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1756101-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | Acadia Pharmaceuticals Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115361-A2 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014739-A1 | Androgen receptor modulators and method of treating disease using the same | NR5A1, AR, CYP17A1 | AR 2/4885 |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | AR 2/4885 |
| US-20080009489-A1 | ANDROGEN RECEPTOR MODULATORS AND METHOD OF TREATING DISEASE USING THE SAME | NR5A1, AR, CYP17A1 | AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.